Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review

Abstract

Livedoid vasculopathy (LV) is an uncommon chronic coagulation disorder whose underlying etiology is not yet fully understood. It predominantly affects females, especially those in late adolescence. There is currently limited research on treatment options for those with this diagnosis. The present systematic review aims to compare the efficacy of rivaroxaban and intravenous immunoglobulin (IVIG) therapy in the treatment of livedoid vasculopathy. A detailed search was conducted from April 20, 2022, to May 1, 2022, using four databases: Elsevier, Medline Complete, Medline Ovid, and PubMed. Out of these, 20 relevant articles were used, and the data was extracted and analyzed. Both rivaroxaban and IVIG were shown to be effective treatment options with similar treatment response times. However, future large-scale clinical trials are needed to determine an established treatment regimen for these patients.

Tratamento De Vasculite Livedoide Secundária a Trombofilias: Revisão Integrativa De Literatura

“…Deve-se destacar também, a terapia com anticoagulantes orais diretos (DOAC), a qual, pode ser usada como terapia de primeira linha 14,21 Além de HBPM e DOAC, imunoglobulinas intravenosas (IgIV) são recomendadas como terapia de primeira linha. Essa terapia não tem uma ação totalmente esclarecida, mas provavelmente age a partir da neutralização de anticorpos circulantes e imunocomplexos depositados nos tecidos.…”

“…IgIV, onde a IgIV atuou na cura em grande parte das úlceras da VL em torno de 2-3 meses, porém apresentou pouca melhora da algia, enquanto a rivaroxabana apresentou melhora significativa tanto da algia quanto das úlceras com tempo médio de resposta de 2-4 meses do início do tratamento 21 .…”